Bone Marrow Testing for Persistent Thrombocytosis
In a patient with persistent thrombocythemia, you should order a bone marrow biopsy with histopathologic examination focusing on megakaryocyte morphology, arrangement, and clustering, along with reticulin staining to assess for fibrosis.
Essential Bone Marrow Tests
Core Biopsy with Histopathology (Required)
The bone marrow biopsy remains mandatory for diagnosing essential thrombocythemia (ET), even in the era of molecular testing 1, 2. The biopsy serves multiple critical functions:
- Differentiates ET from other myeloproliferative neoplasms, particularly prefibrotic/early primary myelofibrosis (PMF), which can present with similar platelet counts but has different prognosis and management 1
- Excludes reactive thrombocytosis in JAK2-negative patients 1
- Rules out myelodysplastic syndromes that may present with thrombocytosis 1
Specific Histopathologic Features to Assess
Megakaryocyte evaluation:
- Look for proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes (characteristic of ET) 1
- Assess megakaryocyte clustering index - ET shows significantly lower clustering compared to myelofibrosis (p<0.001) 3
- Identify "coupling" - a peculiar proliferative feature detected in all ET cases 3
- Evaluate overall megakaryocyte morphology and arrangement patterns 3
Fibrosis assessment:
- Reticulin staining is essential - collagen fibrosis should be absent and reticulin fibrosis minimal or absent in ET 1
- Increased reticulin (grade 1-2) suggests prefibrotic PMF rather than ET 1, 3
Additional histologic markers:
- Bone marrow cellularity - assess for age-appropriate cellularity 4
- Stainable iron - presence helps distinguish myeloproliferative disorders from reactive causes 4
- CD34+ cell quantification - lower in ET compared to myelofibrosis (p=0.001) 3
- MIB-1 (Ki-67) staining - megakaryocyte proliferation index is lowest in ET compared to myelofibrosis 3
- Microvessel density - significantly lower in ET than in myelofibrosis and correlates with fibrosis extent (r=0.861) 3
Critical Diagnostic Context
When Bone Marrow is Particularly Important
Triple-negative cases (JAK2/CALR/MPL-negative): In patients lacking the classic driver mutations, bone marrow histology becomes the primary diagnostic tool. Real-world data shows that 36.8% of triple-negative cases have supportive histology for myeloproliferative neoplasm, and final clinical diagnosis is strongly predicted by histology, not by myeloid gene panels 5. Exercise caution in triple-negative cases even with negative expanded gene panels 5.
Common Pitfalls to Avoid
- Don't skip the bone marrow biopsy even if JAK2 is positive - you still need to exclude prefibrotic PMF, which has worse prognosis 1
- Don't rely solely on aspirate - the biopsy provides architectural information critical for distinguishing ET from early myelofibrosis 3
- Don't overlook iron stores - iron deficiency can mask polycythemia vera; stainable iron assessment is part of the diagnostic workup 1
- Recognize inter-center variability - histologic interpretation varies between centers (36.8% supportive findings reported), so correlation with clinical and molecular data is essential 5
Algorithmic Approach
- Confirm persistent thrombocytosis (platelets ≥450 × 10⁹/L) 1, 2
- Perform molecular testing (JAK2, CALR, MPL) 2
- Order bone marrow biopsy regardless of mutation status 1
- Request specific stains and markers:
- Reticulin stain (mandatory)
- Iron stain
- Consider CD34 and MIB-1 immunostaining for borderline cases
- Ensure pathologist evaluates:
- Megakaryocyte number, size, morphology, clustering
- Degree of fibrosis
- Cellularity
- Trilineage assessment to exclude panmyelosis (PV) or dysplasia (MDS)
The bone marrow biopsy showing proliferation mainly of megakaryocytic lineage with enlarged, mature megakaryocytes, minimal/absent fibrosis, and appropriate clustering patterns is required to establish the diagnosis of ET 1.